Highest-materiality recent filing
Revvity Q1 adj EPS $1.06 beats $1.01 YoY; revenue $711M +7%; plans China IDX divestiture
Q1 GAAP EPS $0.37 vs $0.35 YoY; adjusted EPS $1.06 vs $1.01; revenue $711M (+7% YoY).
Shareholders approved bylaw amendment allowing 25% owners to call special meetings (99,086,661 for, 440,300 against).
Revvity Q4 revenue $772M (+6% YoY), adj EPS $1.70 vs $1.42; initiates 2026 guidance
Q4 GAAP EPS $0.87 vs $0.78; adjusted EPS from cont. ops. $1.70 vs $1.42.
Revvity pre-announces Q4 2025 revenue ~$772M, adj. EPS above guidance
Q4 2025 revenue expected ~$772M, reported +6% and organic +4% YoY.
Revvity Q3: revenue $699M (+2%), GAAP EPS $0.40, adjusted EPS $1.18; raises FY guidance
Revenue $699M, up 2% reported / 1% organic; GAAP EPS $0.40 vs $0.77 a year ago.
Revvity appoints Anita Gonzales as Vice President and Chief Accounting Officer
Anita Gonzales appointed as Vice President and Chief Accounting Officer, effective Oct. 23, 2025.
Revvity Q2 revenue $720M (+4% reported), GAAP EPS $0.46, adjusted EPS $1.18; updates FY2025 guidance
Revenue $720M, +4% reported and +3% organic; GAAP EPS $0.46 vs $0.45 prior year.
Revenue $665M, up 2% reported and 4% organic YoY.
Shareholders approve majority voting standard and special meeting proposal at Revvity annual meeting
Shareholders elected all 10 director nominees with over 96% support; no contested election.
Revvity Q4 revenue $729M (+6% organic), adj EPS $1.42; FY adj EPS $4.90
Q4 revenue $729M (+5% reported, +6% organic); GAAP EPS $0.78 (vs $0.64); adjusted EPS $1.42 (vs $1.25).
Revvity provides preliminary Q4 revenue ~$730M, 6% organic growth; EPS guidance reaffirmed
Q4 preliminary revenue ~$730M; reported growth ~5%, organic ~6% vs. prior year.
Revvity enters new $1.5B revolving credit facility maturing 2030, replaces prior facility
New $1.5B unsecured revolver matures Jan 7, 2030; replaces prior $1.5B facility due Aug 2026.
Revvity Q3 GAAP EPS $0.77, adj. EPS $1.28; raises FY guidance; $1B buyback
Revenue $684M, +2% reported and organic YoY; GAAP operating margin 14.3% vs 10.3%.
Revvity Q2 2024: GAAP EPS $0.45, Adj EPS $1.22; raises full-year adj EPS guidance
Revenue $692M (-2% reported, -1% organic); GAAP EPS $0.45 vs $0.28 YoY.
Revvity Q1 revenue down 4% to $650M; GAAP EPS $0.21 vs $4.50; reaffirms FY guidance
Revenue $650M, -4% reported, -3% organic; GAAP EPS $0.21 vs $4.50 (prior year included large gain from discontinued ops).
Revvity annual meeting approves all proposals, including director elections and say-on-pay
All 10 director nominees elected with majority support; Chapin received most votes (101.9M), Witney fewest (98.7M).
Revvity Q4 revenue $696M (-6%), adjusted EPS $1.25 vs $1.41; full year adjusted EPS $4.65 vs $6.92
Q4 GAAP EPS $0.64 vs $1.01; adjusted EPS $1.25 vs $1.41; revenue down 6% reported, 7% organic.
Revvity elects two new directors; Dr. Sylvie Grégoire not seeking re-election
Dr. Sylvie Grégoire not standing for re-election at the 2024 annual meeting on Apr 23; no disagreement with company.
Q4 2023 revenue expected at least $690M, reported organic revenue decline of approx. 7% and non-COVID organic decline of 4% year-over-year.
On January 25, 2024, the Board elected Michael A. Klobuchar and Sophie V. Vandebroek to serve on the Board, effective February 1, 2024.
On January 25, 2024, the Board elected Michael A. Klobuchar and Sophie V. Vandebroek to serve on the Board, effective February 1, 2024.
On January 25, 2024, Dr. Sylvie Grégoire, a member of the Board of Directors (the “Board”) of Revvity, Inc. (“Revvity” or the “Company”) notified the Company of her decision not to stand for re-election to the Board at the annual meeting of shareholders of the Company scheduled to occur on April 23, 2024.
Max materiality 0.75 · Median 0.70 · Most common event earnings